Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab retreatment with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma
NL-OMON55384Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daratumumab, carfilzomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Rate of very good partial response or better. Started Jul 2019; status: completed.
02
Drugs
daratumumabcarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON55384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55384.